Clinical trial Recruiting at 1 site Interventional Ages 13 to 21

Mindfulness-based neurofeedback for teens with high repetitive negative thinking

Official title: Effect of Mindfulness-based Neurofeedback for Adolescents With Elevated Repetitive Negative Thinking

Run by Massachusetts General Hospital · NCT07055217 · Data updated 2026-11-12

This study will see if real-time fMRI mindfulness-based neurofeedback helps adolescents with high repetitive negative thinking reduce brain network activity linked to rumination compared with a sham procedure and healthy peers.

Quick facts

Study typeInterventional
Ages13 Years to 21 Years
SexAll
Enrollment100 (estimated)
SponsorMassachusetts General Hospital
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedNovember 4, 2025
Main results expectedApril 2027
Study endsApril 2027
Registry record updatedMay 19, 2026
Trial IDNCT07055217 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adolescents aged 13–21 with elevated repetitive negative thinking (PTQ/PTQ-C total score >30 with at least two items rated Often/Almost Always), Tanner stage ≥3, English proficient, and able to use a mobile device for daily surveys are ideal candidates.

Probably not a fit

Patients with lifetime psychotic or bipolar disorders, moderate/severe or recurrent major depression, those who do not meet the specific PTQ score criteria, are younger than 13, or cannot attend the Boston site are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Fifty adolescents with elevated repetitive negative thinking and fifty age- and sex-matched healthy controls (ages 13–21) will be enrolled in a double-blind randomized trial. At-risk participants receive a 45-minute mindfulness training and are then randomized to either active or sham real-time fMRI mindfulness-based neurofeedback, delivered as two 15-minute doses during scanning, while both participants and staff remain blind to assignment. All participants undergo baseline clinical assessment and resting-state fMRI before and after the mindfulness practice, and at-risk adolescents complete daily surveys for about four weeks plus a 4-week follow-up assessment. The main measurements are changes in default mode network (DMN) connectivity and clinical measures of repetitive negative thinking.

Why it matters

Potential benefit: If successful, this approach could reduce repetitive negative thinking and normalize DMN connectivity in adolescents, offering a non-drug option to target rumination.

How similar studies have gone: Small adult and pilot studies of real-time fMRI neurofeedback and related mindfulness-based approaches have shown promising changes in DMN connectivity and rumination, but large randomized trials in adolescents are still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Ages 13-21, inclusive
* If \<18 years old: Competent and willing to provide written informed assent AND have a parent/legal guardian who is competent and willing to provide written informed consent
* If age ≥18 years: Competent and willing to provide written informed consent
* Tanner puberty stage ≥3 (to minimize neuroendocrine variability)
* Able to understand study procedures, read, and write in English
* Access to a mobile device to complete daily surveys

Additional Inclusion Criteria for At-Risk Adolescents - Recurrent negative thinking, defined as PTQ/PTQ-C total score \>30 with at least two items rated as 3 (Often) or 4 (Almost Always)

Additional Inclusion Criteria for Healthy Controls

-PTQ/PTQ-C total score \<15, with zero items rated as 3 (Often) or 4 (Always)

Exclusion Criteria:

* Any of the following lifetime mental health disorders by DSM-V criteria: psychotic disorders, bipolar disorder, recurrent moderate or severe major depressive disorder, conduct disorder, developmental disorder (e.g., autism), post-traumatic stress disorder, or obsessive compulsive disorder
* Severe lifetime substance use disorder
* Unstable medical or neurologic condition as determined by study staff, history of epilepsy or seizure disorder, head injury, loss of consciousness \>5 minutes by participant self-report
* MRI contraindications (i.e. presence of ferromagnetic implants, cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, magnetic dental implants claustrophobia).
* Visual, auditory, or cognitive impairment (IQ\<80 based on the Wechsler Abbreviated Intelligence Scale (WASI)) that may make it difficult to participate.
* Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol.
* Pregnancy: a negative pregnancy test is required at the time of enrollment for any individuals of childbearing potential
* Individuals who are under the legal protection of the government or state (Wards of the State)

Where it's running

  • Massachusetts General Hospital, Center for Addiction Medicine, 101 Merrimac Street, Suite 320, Boston, MA 02114
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.